News AstraZeneca PLC Deutsche Boerse AG

Stocks

ZEG

GB0009895292

Pharmaceuticals

Market Closed - Deutsche Boerse AG 08:50:55 2026-08-20 EDT			After hours 16:00:01
140.05 ^EUR	-1.23%		140.85	+0.57%

10:32am	Pharma sector doubles down on AI amid hopes of slashing costs, timelines	RE
09:59am	Cancer vaccines finally garner the spotlight

All News

Mentions Relevance

09:52am	Foresite Labs Appoints Dr. Jorge Reis-Filho to Chief Strategy Officer and Operating Partner; Joins Foresite Capital as Venture Partner	AQ
02:49am	AstraZeneca PLC : Goldman Sachs reaffirms its Buy rating	ZD
08-19	AstraZeneca PLC : Deutsche Bank reiterates its Sell rating	ZD
08-19	AstraZeneca PLC : UBS reiterates its Buy rating	ZD
08-18	AstraZeneca - Update on eVOLVE-Lung02 Phase III trial of volrustomig plus chemotherapy in metastatic non-small cell lung cancer	AQ
08-17	Health Care Down on Growth Doubts - Health Care Roundup	DJ
08-17	UK Shares Start Week Downbeat; AstraZeneca Shares Data from Lung Cancer Trials	MT
08-17	European Stocks Close Lower in Monday Trading Despite Tech, Mining Stocks Rally	MT
08-17	BofA Notes AstraZeneca's Volrustomig Late-stage Study Fail; Buy Maintained	MT
08-17	ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated statistically significant and clinically meaningful improvement in PFS as 1st-line treatment of patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial	BU
08-17	TAGRISSO® (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO	BU
08-17	AstraZeneca Demonstrates Statistically Significant and Clinically Meaningful Improvements with TAGRISSO Plus Savolitinib in Saffron Phase III Trial	CI
08-17	AstraZeneca Discontinues EVOLVE-Lung02 Phase III Trial Of Volrustomig Plus Chemotherapy In Metastatic Non-Small Cell Lung Cancer	CI
08-17	HUTCHMED Announces ORPATHYS plus TAGRISSO Demonstrated Statistically Significant and Clinically Meaningful Improvements in Progression-Free and Overall Survival in MET-Driven EGFR-Mutated Lung Cancer	AQ
08-17	AstraZeneca PLC : JP Morgan remains its Buy rating	ZD
08-17	AstraZeneca Ends Phase Three Lung Cancer Drug Trial After Review -- Update	DJ
08-17	AstraZeneca Halts Lung Cancer Trial for Volrustomig; Reports Positive Data for Tagrisso Combo, Enhertu	MT
08-17	AstraZeneca halts lung trial as two cancer drugs show positive results	AN
08-17	AstraZeneca Reports Positive Results with Lung Cancer Drugs	MT
08-17	AstraZeneca Discontinues Phase 3 Lung Cancer Trial for Volrustomig Combination	MT
08-17	Triple news for AstraZeneca
08-17	AstraZeneca, Daiichi Sankyo's Enhertu Improves Progression-free Survival in Late-stage Lung Cancer Trial	MT
08-17	AstraZeneca ends one trial; Telecom Plus backs view	AN
08-17	AstraZeneca Ends Phase Three Lung Cancer Drug Trial After Review	DJ
08-17	AstraZeneca : Enhertu demonstrated statistically significant and clinically meaningful improvement in progression-free survival as 1st-line treatment of patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial	PU